The 6 analysts offering 12-month price forecasts for Syndax Pharmaceuticals Inc have a median target of 30.50, with a high estimate of 32.00 and a low estimate of 21.00. The median estimate represents a +64.16% increase from the last price of 18.58.
The current consensus among 7 polled investment analysts is to Buy stock in Syndax Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.59
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.